JAK2
V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders The JAK2 1849G4T mutation results in valine to phenylalanine substitute at 617 amino acid (JAK2 V617F ), and this molecular change occurs in most patients with polycythemia vera (PV) and in approximately 50% of patients with essential thrombocythemia (ET) or chronic idiopathic myelofibrosis (CIMF). [1] [2] [3] [4] Mitotic recombination at the terminal portion of the 9p region is considered to produce homozygous JAK2 V617F , and approximately 20-30% of PV patients have homozygous JAK2 V617F whereas most ET patients have heterozygous JAK2
V617F3 . However, it is still controversial whether JAK2 V617F is a primary genetic event in CMPD, and the frequency of homozygous JAK2 V617F varied in different reports, probably owing to technical differences or diagnostic criteria. 5 To clarify the biological and clinical features in JAK2 V617F -positive cells in CMPD, we attempted to measure the proportion of mutated alleles of JAK2 semiquantatively by the sequence-specific primer-single molecule fluorescence detection (SSP-SMPD) assay. 6 We studied JAK2 V617F in 211 individuals, including 103 patients with chronic myeloproliferative disorders (CMPD): 34 patients with PV, 51 with ET, nine with CIMF, five with chronic myeloid leukemia (CML) with myelofibrosis, one hypereosinophilic syndrome (HES) with myelofibrosis and three patients with unclassifiable CMPD. For the SSP-SMFD study, 10 ng of extracted DNA was amplified by the first-round polymerase chain reaction (PCR), and then extended by the fluorescencelabeled single nucleotide polymorphism (SNP)-specific primer. 6 To obtain reproducible results and to clarify the quantitative relationship between mutated allele and wild-type allele in the sample, we calculated the ratio of K2(T)/K2(G)% Â 100 (K2(T)/ K2(G)% ratio). 6 We mixed two reference plasmids with various ratios (percentages of mutation allele-specific oligonucleotide, that is, puc18_T: 0-100%), and we found that this method detects at least a 5% mixture of the T-specific population, that is, at least 10% of the population with heterozygous JAK2 V617F (data not shown). JAK2 V617F was detected in only three of the 85 patients with non-CMPD hematologic diseases, that is, three MDS with myelofibrosis (Supplementary Information 1). 6 All other normal subjects, cases of secondary erthrocytosis, acute and chronic leukemias, unclassified CMPD, HES and CMML had wild-type JAK2. Based on the new WHO criteria, 92.6% (25/27) of PV patients had JAK2
V617F with 18 heterozygous and seven homozygous JAK2 V617F . Two out of seven homozygous JAK2 V617F were judged as heterozygous JAK2 V617F by the PCR direct-sequence assay. All seven patients who did not meet the WHO criteria (non-WHO PV) had wild-type JAK2. Thirty-two of 51 ET patients (62.7%) had JAK2 V617F with 31 heterozygous and one homozygous JAK2
V617F by the SSP-SMFD: four ET patients judged as wild-type JAK2 by the PCR direct sequence were identified as heterozygous JAK2
V617F by the SSP-SMFD. Of the nine patients with CIMF, five had wild-type, three had heterozygous and one had homozygous JAK2
V617F
. This clearly indicates that the SSP-SMFD assay may be more sensitive for the detection of mutated alleles than the PCR direct sequence.
PV patients without JAK2 V617F (seven non-WHO PV plus two WHO-PV: all male) had a significantly lower leukocyte count, a lower platelet count and a lower frequency of palpable splenomegaly and requiring cytoreductive chemotherapy, when compared to PV patients with JAK2
V617F (Supplementary file 2) .
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Of the JAK2 V617F -positive WHO-PV, patients with homozygous JAK2 V617F had a significantly higher frequency of splenomegaly (P ¼ 0.0057), but not significantly higher development of myelofibrosis (P ¼ 0.0748) or abnormal karyotypes (P ¼ 0.0748). The duration between the diagnosis and the timing of JAK2 V617F examination was longer, but not with statistical significance (P ¼ 0.0597) ( Table 1 ). Of the group of patients with JAK2 V617F , splenomegaly (P ¼ 0.0267) and chromosomal abnormality (P ¼ 0.0366) were significantly prominent in PV patients developing myelofibrosis.
Of the ET patients, leukocyte counts and hemoglobin levels were significantly elevated in ET patients with JAK 2V617F but there was no difference in platelet count. Patients with JAK2 V617F had a high frequency of a thrombotic history (P ¼ 0.0493) and abnormal karyotypes (P ¼ 0.0283) ( Table 2) . ET patients with a thrombotic history had a higher platelet count (P ¼ 0.031), and tended to have higher leukocyte count (P ¼ 0.0597) and hemoglobin level (P ¼ 0.0651). This tendency was also confirmed in the group of ET patients with JAK2 V617F ; patients with a history of thrombosis had higher platelet counts (P ¼ 0.0460).
The new WHO criteria might be strict in diagnosing PV patients. James et al. 7 found that none of the non-PV patients according to the WHO criteria had JAK2 V617F whereas eight out of 29 patients of the non-PV by the PVSG criteria presented the mutation. The difference between non-WHO-PV and WHO-PV with wild-type JAK2 was only the presence of splenomegaly, with no significant difference in hematologic parameters. Moreover, two WHO-PV patients with wild-type JAK2 were treated with phlebotomy alone. This indicates that non-WHO-PV patients were selectively eliminated owing to the lack of palpable splenomegaly at PV diagnosis and normal range of serum erythropoietin levels; no patients with non-WHO PV or WHO PV without JAK2 V617F showed elevated leukocytes or platelets. This may suggest the possibility that a JAK2 V617F - Abbreviations: F, female; M, male; PV, polycythemia vera. Abbreviations: ET, essential thrombocythemia; F, female; M, male.
Letters to the Editor negative clone in polycythemia patients is present at an earlier stage, perhaps as a primary event. Therefore, we should pay more attention to pathophysiological events related to the JAK2 V617F -negative clone in CMPD, including PV. In the ET patients, higher leukocyte and higher hemoglobin level were evident in JAK2 V617F -positive patients, indicating that CMPD with JAK2 V617F constitutes a common proliferative characteristic.
Kralovics et al. 3 also noted that CMPD with JAK2 V617F showed a higher incidence of secondary myelofibrosis, hemorrhage, thromboembolic events and requirement of treatment. In our PV patients, the presence of JAK2 V617F affected hematologic features, whereas homozygous JAK2 V617F was linked to clinical features, that is, splenomegaly and tendency toward myelofibrosis. However, it might be difficult to clearly separate patients with heterozygous JAK2 V617F from those with homozygous JAK2 V617F with a low percentage of cells, owing to technological limitations. Scott et al. 8 demonstrated that V617F-homozygous erythroid progenitors are present in most patients with PV, thus providing the possibility that the difference between heterozygous and homozygous JAK2 V617F may represent an occupancy of JAK2 mutation-positive cells.
In conclusion, detection of JAK2 V617F , especially estimation of cells with mutated alleles, in combination with hematologic features, is important in managing CMPD patients. The presence of JAK2 mutation, either heterozygous or homozygous JAK2 V617F , links to pan-myelolysis (leukocytosis, erythrocytosis and thrombocytosis), namely JAK2 V617F -positive CMPD. Nevertheless, some possibilities for discrepancy of JAK2 V617F detectability are discussed; studies on JAK2 V617F -negative clone in CMPD patients might also be important to disclose the pathophysiology of each CMPD category. Although the number of patients examined in the current study is small, our results may suggest that the mutational status of JAK2 V617F is associated with clinical features that represent disease progression of various CMPD subtypes.
